Mandate

Vinge advises industrifonden in connection with pharmalink’s capital raising of sek 96 million

October 08, 2013

Industrifonden and the Norwegian investment company, Investinor have invested a combined total of SEK 79 million in Pharmalink, the pharmaceuticals development company. Private investors have also contributed to the total capital raising of SEK 96 million. The funds will be used to further develop Pharmalink’s product portfolio.

Pharmalink is a pharmaceuticals company which improves and further develops existing pharmaceuticals. The company is currently conducting the Nefecon project for the treatment of inflammation of the kidneys and the Busulipo project for treatment prior to bone marrow transplantation.

Industrifonden has been a stakeholder in Pharmalink since 2004. The Norwegian investment company, Investinor is a new stakeholder.

Vinge partner Johan Larsson advised Industrifonden

Related

Vinge advises Axcel VI and Currentum in connection with the acquisition of Elprojekt Skandinavien

Vinge advises Axcel VI and the Currentum Group in connection with the acquisition of Elprojekt Skandinavien. The company provides complete electrical installations throughout Sweden, focusing on new construction of logistics properties, production facilities, residential buildings and office buildings. Elprojekt Skandinavien had a revenue of SEK 316 million in 2024.
June 23, 2025

Vinge advises Meribel Pharma Solutions

Vinge advises Meribel Pharma Solutions in connection with the sale of a production facility specialising in the manufacture of antibiotics to Apotek Produktion & Laboratorier AB ("APL").
June 23, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 232 million and restructuring of debt financing

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue, through which Hansa raises gross proceeds of approx. SEK 232 million, and restructuring of debt financing. As part of such debt restructuring, Hansa has in conjunction with the directed share issue set-off debt corresponding to approximately USD 14.9 million of its total debt amount.
June 23, 2025